サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1702368

幹細胞バンキングの世界市場：2025年～2033年

Global Stem Cell Banking Market - 2025-2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
幹細胞バンキングの世界市場：2025年～2033年
出版日: 2025年04月10日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の幹細胞バンキングの市場規模は、2024年に116億6,000万米ドルに達し、2033年には240億2,000万米ドルに達すると予測され、2025年から2033年の予測期間中のCAGRは8.6％と見込まれています。

世界の幹細胞バンキング市場は、医療や治療を目的とした幹細胞の収集、加工、長期保存を専門とする分野として急速に拡大しています。これらのバンクは、臍帯血、骨髄、脂肪組織など様々な供給源に由来する幹細胞を保存し、将来の再生治療に利用できるようにしています。

幹細胞は、白血病のような血液疾患、自己免疫疾患、変性疾患など、幅広い疾患の治療に重要な役割を果たしています。バイオテクノロジーの進歩に伴い、幹細胞バンキングは個別化医療の重要な一部となりつつあり、個人が将来の治療に使用する可能性のある幹細胞を保存できるようになっています。

幹細胞研究と再生医療の急速な進歩は、世界の幹細胞バンキング市場の成長を促進する1次要因の1つです。これらの進歩により、様々な疾患の治療における幹細胞の応用が拡大し、ヘルスケアの成果が向上しています。

さらに、主要企業の製品発表や幹細胞研究の進歩が、幹細胞バンキング市場の成長を後押ししています。例えば、Bioserve Indiaは2024年7月、REPROCELLとの共同開発による最新の幹細胞製品シリーズをインドで発表しました。これらの革新的な製品は、インド市場における科学研究、医薬品開発、再生医療、治療法の発見を推進するために設計されています。

企業や研究機関は幹細胞の研究開発に多額の投資を行っており、新製品の発売やより優れたバンキングサービスの提供につながっています。Bioserve IndiaとREPROCELLの提携のような最近の共同研究は、先進的な幹細胞製品を発表し、市場の成長を後押ししています。幹細胞バンキング市場は、再生医療の進歩、継続的な研究開発の進展、個別化治療に対する需要の高まりにより急成長しています。

世界の幹細胞バンキング市場における主要な抑制要因の一つは、幹細胞の収集、処理、保管、維持に関連する運用コストの高さです。これらのコストは、幹細胞バンキングサービスの利用しやすさ、利用しやすさ、特に個人での保管に大きな影響を与えます。出生時に臍帯血を採取するには、医療従事者、専門的な機器、研究室への輸送などが必要となります。

当レポートでは、世界の幹細胞バンキング市場について調査し、市場の概要とともに、細胞由来別、バンクタイプ別、サービスタイプ別、用途別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
    • 機会
    • 影響分析

第4章 戦略的洞察と業界見通し

  • 市場のリーダーとパイオニア
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第5章 幹細胞バンキング市場（細胞由来別）

  • 成体幹細胞
    • 造血幹細胞（HSC）
    • 間葉系幹細胞（MSC）
  • 胚性幹細胞
  • 人工多能性幹細胞（iPSC）
  • その他

第6章 幹細胞バンキング市場（バンクタイプ別）

  • 公的幹細胞バンキング
  • 民間の幹細胞バンキング

第7章 幹細胞バンキング市場（サービスタイプ別）

  • サンプルの保存と保管
  • サンプルの分析
  • サンプルの処理
  • サンプルの収集と輸送

第8章 幹細胞バンキング市場（用途別）

  • 再生医療
  • 医薬品の発見と開発
  • 疾患モデル
  • 細胞ベースの治療法
  • その他

第9章 幹細胞バンキング市場、地域別市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
  • 中東・アフリカ

第10章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要市場参入企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併・買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第11章 企業プロファイル

  • Cryo-Cell International, Inc.
    • 会社概要
    • 製品ポートフォリオ
    • 財務概要
    • 主な発展
    • SWOT分析
  • CBR Systems, Inc.
  • ViaCord, LLC
  • LifeCell
  • StemCyte India Therapeutics Pvt. Ltd
  • Smart Cells International Limited.
  • Cryoviva India.
  • Cordlife.
  • VITA 34
  • Biocell

第12章 仮定と調査手法

第13章 付録

目次
Product Code: BT860

The global stem cell banking market reached US$ 11.66 billion in 2024 and is expected to reach US$ 24.02 billion by 2033, growing at a CAGR of 8.6 % during the forecast period of 2025-2033.

The global stem cell banking market is a rapidly expanding sector dedicated to the collection, processing, and long-term storage of stem cells for medical and therapeutic purposes. These banks preserve stem cells derived from various sources, such as umbilical cord blood, bone marrow, and adipose tissue, ensuring their availability for future regenerative treatments.

Stem cells play a crucial role in treating a wide range of conditions, including blood disorders like leukemia, autoimmune diseases, and degenerative illnesses. With advancements in biotechnology, stem cell banking is becoming an essential part of personalized medicine, allowing individuals to store their stem cells for potential use in future therapies.

Market Dynamics: Drivers & Restraints

Advancements in Stem Cell Research & Regenerative Medicine

The rapid progress in stem cell research and regenerative medicine is one of the primary drivers fueling the growth of the global stem cell banking market. These advancements are expanding the applications of stem cells in treating various diseases and improving healthcare outcomes.

Additionally, key players' product launches and advancements in stem cell research drive this stem cell banking market growth. For instance, in July 2024, Bioserve India introduced its latest range of advanced stem cell products in India, developed in collaboration with REPROCELL. These innovative products are designed to drive progress in scientific research, drug development, regenerative medicine, and therapeutic discovery within the Indian market.

Companies and research institutions are investing heavily in stem cell R&D, leading to new product launches and better banking services. Recent collaborations like Bioserve India's partnership with REPROCELL have introduced advanced stem cell products, boosting market growth. The stem cell banking market is growing rapidly due to advancements in regenerative medicine, continuous R&D progress, and rising demand for personalized medical treatments.

High Operational Costs of Stem Cell Banking

One of the major restraints in the global stem cell banking market is the high operational costs associated with collecting, processing, storing, and maintaining stem cells. These costs significantly impact the affordability and accessibility of stem cell banking services, particularly for private storage options. Collecting umbilical cord blood at birth involves medical personnel, specialized equipment, and transportation to the laboratory.

Segment Analysis

The global stem cell banking market is segmented based on cell source, bank type, service type, application, and region.

Cell Source:

The adult stem cells segment in the cell source is expected to dominate the global stem cell banking market with the highest market share

The adult stem cells segment plays a crucial role in the global stem cell banking market, offering a valuable source for regenerative medicine, disease treatment, and tissue repair. Adult stem cells, primarily derived from bone marrow, adipose tissue, and peripheral blood, are widely utilized due to their established clinical applications and minimal ethical concerns compared to embryonic stem cells.

The demand for these cells has been increasing due to advancements in regenerative medicine, particularly in treating degenerative diseases such as osteoarthritis, cardiovascular conditions, and neurological disorders. Additionally, ongoing research and clinical trials continue to validate their effectiveness, further driving their adoption in stem cell banking services.

For instance, in January 2023, TTP launched a spin-out company, Cellular Origins, to enhance the scalability of adult stem cell manufacturing for regenerative medicine and advanced therapies. The company's proprietary technology automates sterile fluidic interconnections, enabling seamless integration with existing and future bioprocess equipment.

This innovation aims to streamline production, ensuring cost-effective and efficient manufacturing of adult stem cell therapies, which are increasingly used in treating various degenerative diseases and injuries. These factors have solidified the segment's position in the global stem cell banking market.

Geographical Analysis

North America is expected to hold a significant position in the global stem cell banking market, with the highest market share

The North American stem cell banking market is experiencing significant growth due to several key drivers. One of the primary factors is the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders. Approximately 60% of Americans have at least one chronic illness, creating a rising demand for regenerative medicine and stem cell therapies. Additionally, the growing incidence of genetic disorders, infertility, and reproductive health concerns is contributing to the expansion of the market.

Another major driver is the well-established healthcare infrastructure and strong research and development (R&D) initiatives in North America. The region is home to leading biotech companies and research institutions that are actively working on stem cell-based therapies. Government initiatives and private investments in personalized medicine and regenerative treatments are further propelling market growth.

For instance, in September 2024, Acorn Biolabs launched its stem cell banking service in North America and has since partnered with over 70 clinics. The company focuses on non-invasive stem cell preservation by collecting and cryogenically storing hair follicle-derived cells. This process allows individuals to preserve younger, more regenerative cells for potential future therapies, particularly in anti-aging and regenerative medicine. Thus, the above factors are consolidating the region's position as a dominant force in the global stem cell banking market.

Competitive Landscape

The major global players in the stem cell banking market include Cryo-Cell International, Inc., CBR Systems, Inc., ViaCord, LLC, LifeCell, StemCyte India Therapeutics Pvt. Ltd, Smart Cells International Limited, Cryoviva India, Cordlife, VITA 34, and Biocell, among others.

Key Developments

  • In May 2024, Bioz, an AI-powered software company, partnered with WiCell, a leader in stem cell characterization and banking, to integrate product citation data into the WiCell website. This collaboration introduces the Bioz Content Hub, an interactive tool that allows researchers to explore real-time product citations for WiCell's stem cell lines.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global stem cell banking market report delivers a detailed analysis with 70 key tables, more than 65 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Cell Source
  • 2.4. Snippet by Bank Type
  • 2.5. Snippet by Service Type
  • 2.6. Snippet by Application
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Advancements in Stem Cell Research & Regenerative Medicine
      • 3.1.1.2. Increasing Prevalence of Chronic and Genetic Diseases
    • 3.1.2. Restraints
      • 3.1.2.1. High Operational Costs of Stem Cell Banking
      • 3.1.2.2. Risk of Contamination and Cell Viability Issues
    • 3.1.3. Opportunity
      • 3.1.3.1. Expansion of Hybrid Stem Cell Banks
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with the largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Forces Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Stem Cell Banking Market, By Cell Source

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Cell Source
    • 5.1.2. Market Attractiveness Index By Cell Source
  • 5.2. Adult Stem Cells*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Hematopoietic Stem Cells (HSCs)
      • 5.2.3.1. Bone Marrow-Derived Stem Cells
      • 5.2.3.2. Peripheral Blood Stem Cells (PBSCs)
    • 5.2.4. Mesenchymal Stem Cells (MSCs)
      • 5.2.4.1. Adipose Tissue-Derived Stem Cells
      • 5.2.4.2. Dental Pulp Stem Cells
  • 5.3. Embryonic Stem Cells
  • 5.4. Induced Pluripotent Stem Cells (iPSCs)
  • 5.5. Others

6. Stem Cell Banking Market, By Bank Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bank Type
    • 6.1.2. Market Attractiveness Index By Bank Type
  • 6.2. Public Stem Cell Banks*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Private Stem Cell Banks

7. Stem Cell Banking Market, By Service Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 7.1.2. Market Attractiveness Index By Service Type
  • 7.2. Sample Preservation and Storage*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Sample Analysis
  • 7.4. Sample Processing
  • 7.5. Sample Collection and Transportation

8. Stem Cell Banking Market, By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Regenerative Medicine*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Drug Discovery and Development
  • 8.4. Disease Modeling
  • 8.5. Cell-based Therapies
  • 8.6. Others

9. Stem Cell Banking Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bank Type
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
      • 9.2.7.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bank Type
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bank Type
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Brazil
      • 9.4.7.2. Argentina
      • 9.4.7.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bank Type
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bank Type
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. Cryo-Cell International, Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals, etc.
    • 11.1.5. SWOT Analysis
  • 11.2. CBR Systems, Inc.
  • 11.3. ViaCord, LLC
  • 11.4. LifeCell
  • 11.5. StemCyte India Therapeutics Pvt. Ltd
  • 11.6. Smart Cells International Limited.
  • 11.7. Cryoviva India.
  • 11.8. Cordlife.
  • 11.9. VITA 34
  • 11.10. Biocell

LIST NOT EXHAUSTIVE

12. Assumptions and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us